- Home
- AUST vs XCUR Comparison
AUST vs XCUR Comparison
Compare AUST & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | XCUR |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 13.7M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AUST | XCUR |
|---|---|---|
| Price | $0.95 | $1.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.6K | ★ 241.2K |
| Earning Date | 05-06-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $1.43 |
| 52 Week High | $3.92 | $9.48 |
Technical Indicators
Market Signals| Indicator | AUST | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 39.05 | 38.58 |
| Support Level | $0.92 | $1.71 |
| Resistance Level | $1.42 | $3.40 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 26.50 | 45.31 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration, and evaluation of mineral resource properties in the western United States of America (USA). The exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek, Lone Mountain, Stockade Mountain, Fourmile Basin, and Miller.
About XCUR Exicure Inc.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.